Rtw Investments 13F: Adds $4.9M to AQST Stake

Rtw Investments has boosted its stake in AQST, adding 1,176,471 shares. This increase brought their total holdings to 7,426,471 shares, valued at approximately $30.97 million as of the latest SEC filing. This adjustment represents an 18.8% increase from their previous position.

What Changed in Rtw Investments's AQST Position

Rtw Investments increased its holdings in AQST by 1,176,471 shares, growing its stake by nearly 19% to a total of 7,426,471 shares. This boost in shares reflects a significant commitment to the company, with the total value of the holdings now standing at about $30.97 million.

Other Institutional Activity in AQST

Bratton Capital Management held steady with 9,810,958 shares valued at $40.72 million. BlackRock, Inc. trimmed its position by 266,331 shares, leaving it with 7,509,071 shares worth $31.16 million. Vanguard Capital Management LLC added 4,443,698 shares, bringing its total to the same number, valued at $18.44 million. Federated Hermes, Inc. increased its position by 907,517 shares to 2,940,339 shares, valued at $12.20 million. Balyasny Asset Management L.P. made a significant addition, increasing by 1,929,631 shares to a total of 2,900,570 shares, valued at $12.04 million.

Aquestive Therapeutics, Inc. Stock Up 2.7%

Shares of AQST traded around $4.17. The company does not have a meaningful P/E ratio as it isn't currently profitable. The stock's 52-week range is between $3.50 and $5.50. The 50-day moving average stands at $4.00, while the 200-day moving average is $4.25.

Insider Buying and Selling at Aquestive Therapeutics, Inc.

On June 10, 2026, several insiders engaged in transactions involving AQST shares. Gregory Brown, Julie Krop, Marco Taglietti, John Cochran, and Timothy Morris each purchased 50,500 shares. Abigail Jenkins sold 50,500 shares on the same day. None of these transactions were part of a pre-planned trading program.

Analysts Set New Price Targets

Analysts have been active in setting price targets for AQST. On November 7, 2025, Piper Sandler maintained a 'buy' rating with an $8.00 target. JMP Securities also maintained a 'buy' rating with a $12.00 target on October 9, 2025. Oppenheimer maintained a 'buy' rating with an $8.00 target on September 8, 2025, and assumed coverage with a 'buy' rating and a $7.00 target on June 2, 2025. HC Wainwright & Co. reiterated a 'buy' rating with a $10.00 target on March 10, 2025.

About AQST

AQST is a pharmaceutical company that focuses on developing and commercializing innovative products for the treatment of central nervous system diseases and other medical conditions. The company is headquartered in the United States and aims to enhance patient outcomes through its proprietary drug delivery technologies.

Bottom Line

Rtw Investments' decision to increase its stake in AQST by nearly 19% is a notable move that reflects its confidence in the company's potential. Investors often track such filings to gauge institutional sentiment, though it's important to remember that 13F filings are backward-looking and may not represent current positions. AQST's stock performance and insider activities, along with analyst ratings, provide further context for those following the company's developments.